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Identity 




Location of the human PLD2 (hPLD2) gene is 
chromosome 17: 4710391 ~ 4726729 (forward strand) 
(Ensembl database: gene: PLD2, ENSG00000129219). 
hPLD2 has 25 exons and 24 coding exons. 
Transcription 
Two transcripts of hPLD2 (hPLD2A and hPLD2B) 
code long-range proteins.  
As shown in figure 1, splicing variation in exon 23 
gives rise to an 11 amino acid difference between the 
two. hPLD2A has a 3503 bp mRNA (933 amino acids) 
and hPLD2B has a 3391 bp mRNA (922  
amino acids) (Ensembl database: PLD2A (transcript: 
ENST00000263088, protein: ENSP0000026308), 




Two products of hPLD2 can be generated by two 
transcripts (splicing variants). hPLD2A has 933 amino 
acids and hPLD2B has 922 amino acids. hPLD2B 
contains 11 amino acid deletions as compared with 
hPLD2A.  
These two products have evolutionally conserved 
domains.  
Like other members of the PLD superfamily, PLD2 
also has a HKD domain (HxKxxxxDxxxxxxGSxN, x = 
any amino acid), which is essential for mediating PLD 
enzymatic activity (Frohman et al., 1999; Exton, 200 ; 
Jenkins and Frohman, 2005).  
 
Figure 1. Organization of exons and introns in the human PLD2 (hPLD2) gene. Red rectangles (open and close) indicate exons and 
dark blue lines represent introns. Open red rectangles are non-coding exons and close red rectangles are coding exons. Blue rectangles 
indicate splicing variants in exon 23 of PLD2A and PLD2B. The diagram is not drawn to scale. 
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Figure 2. Organization of domains in hPLD2 protein. PX represents the phox homology (PX) domain, and PH indicates the pleckstrin 
homology (PH) domain. HKD represents the HKD domain (HxKxxxxD, x = any amino acid), which is the catalytic domain. The blue arrow 
indicates region that differ in hPLD2A and hPLD2B. The diagram is not drawn to scale. 
 
The phox homology (PX) domain and the pleckstrin 
homology (PH) domain are known to be involved in 
interactions with lipids and other proteins (Frohman et 
al., 1999; Sung et al., 1999; Exton, 2002). In particular, 
the PLD2-PX domain has been reported to interact with
a variety of proteins, such as, dynamin, PLCγ, dk5, 
Grb2, and munc18 (Lee et al., 2009). In addition, the 
PLD2-PH domain is also involved in the interaction 
with Src and Rac2 (Ahn et al., 2003; Mahankali et al., 
2011). 
The PLD2-PX domain can act as a guanine nucleotide 
exchange factor (GEF) for dynamin to enhance 
endocytosis and as a GEF for RhoA to induce LPA-
mediated stress fiber formation (Lee et al., 2006; Jeon 
et al., 2011). Furthermore, the PLD2-PH domain can 
act as a GEF for Rac2 (Mahankali et al., 2011). Ckd5 
has been reported to phosphorylate the PLD2-PX 
domain (Ser 134), and thus, mediate PLD2 activation 
and the secretion of insulin in a pancreatic β ell line 
(Lee et al., 2008a). Src also can interact with the PLD2-
PH domain and phosphorylate PLD2 to mediate EGF-
induced Src activation (Ahn et al., 2003). The 
Y169/Y179 residues of PLD2-PX domain are critically 
implicated in the interaction with Grb2 (Di Fulvio et 
al., 2006). This interaction is known to be important for 
the activation and intracellular localization of PLD2. In 
addition, the dissociation of munc-18 from the PLD2-
PX domain is essential for EGF-induced PLD2 
activation (Lee et al., 2004). The PLD2-PX domain 
interacts with the PLCγ-SH3 domain to mediate the 
EGF-induced activations of PLD2 and PLCγ (Jang et 
al., 2003). In addition to interacting with proteins, the 
PLD2-PH domain can interact with phosphoinositide 
4,5-bisphosphate (PtdIns (4,5)P2), and this interacion 
is known to be important for the intracellular 
localization of PLD2 (Honda et al., 1999; Hodgkin et 
al., 2000; Sciorra et al., 2002). In the primary 
structures, the main difference between PLD1 and 
PLD2 is a loop region, that is, PLD1 has this region, 
whereas PLD2 does not (Colley et al., 1997; Hammond 
et al., 1997; Du et al., 2000; Peng and Frohman, 2012). 
It is considered that the loop region in PLD1 has 
autoinhibitory activity. 
Expression 
PLD2 has been reported to be expressed in a variety 
type of tissues, such as, ovary, placenta, prostate, spinal 
cord, trachea, thymus, and thyroid. Specially, PLD2 
mRNA has been detected in many different brain 
regions (Peng and Rhodes, 2000). During rat brain 
development, PLD2 mRNA levels are elevated and 
peak in the adult brain. In addition, PLD2 mRNA 
levels are transiently reduced during cerebral hypoxic-
ischemic injury (Peng et al., 2006). Vessel occlusion-
induced hypoxia in the hippocampus has been reported 
to increase PLD2 levels (Min do et al., 2007). 
Furthermore, the expression of PLD2 is known to be 
significantly elevated in many cancers, including 
breast, renal, and colon cancer (Zhao et al., 2000; Saito 
et al., 2007; Wood et al., 2007). 
Localisation 
Most studies have found PLD2 is mainly localized in 
the plasma membrane (Du et al., 2004) and that PLD1 
is primarily localized in specialized vesicles, such as, 
endoplasmic reticulum (ER), Golgi apparatus, secretory 
vesicles, endosomes, and lysosomes (Brown et al., 
1998; Freyberg et al., 2001), and several reports 
indicate that PLD2 is also localized in cytoplasmic 
vesicles (Divecha et al., 2000). In addition, PLD2 can 
be translocated into the submembranous vesicles by 
serum and ruffling membranes by epidermal growth 
factor (EGF) (Colley et al., 1997; Honda et al., 1999). 
As mentioned above, the interaction between the 
PLD2-PH domain and PtdIns (4,5)P2 is important for 
the localization of PLD2. A PLD2-PH domain mutant 
incapable of interacting with PtdIns (4,5)P2 was not 
localized to the plasma membrane like wild-type PLD2, 
but localized to punctuate structures in cytoplasm 
(Sciorra et al., 2002). 
Function 
PLD2 is a phosphatidylcholine (PC)-hydrolyzing 
enzyme and generates choline and phosphatidic acid 
(PA) (Jenkins and Frohman, 2005). PLD2 can be 
activated by multiple extracellular ligands and the 
major roles of PLD2 can be achieved by PA generation. 
PA is considered as a second messenger that mediates a 
variety of cellular functions such as, proliferation, cell 
growth, vesicle trafficking (endocytosis and 
exocytosis), and actin-cytoskeletal arrangement (Park 
et al., 2012). Furthermore, animal studies have shown 
that PLD2 can serve as a key mediator of in vivo 
pathophysiologic functions (Oliveira et al., 2010). 
Regardless PA generation, PLD2 protein can act as a
GTPase-activating protein (GAP) for dynamin and a 
GEF for RhoA and Rac2 (Lee et al., 2006; Jeon et al., 
2011; Mahankali et al., 2011). It is known that these 
functions of PLD2 and PA can be mediated by their 
binding partners (Jang et al., 2012). Currently, PLD2 
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and PA are known to have about 40 and 50 binding 
partners, respectively. Interacting partners include 
various classes of proteins (kinase, phosphatase, 
GTPase, structural protein, transporter, adapter, 
phospholipase, transcription factor), and phospholiids 
(PA, PtdIns5P, PtdIns(4,5)P2, and PtdIns(3,4,5)P3). 
Proliferative signaling 
Multiple extracellular mitogenic signals, such as, EGF, 
platelet-derived growth factor (PDGF), and vascular 
endothelial growth factor (VEGF) can activate PLD2 to 
generate PA (Lee et al., 2009; Park et al., 2012). 
Specially, PLD2 is known to be implicated in EGF-
mediated cell proliferation (Ahn et al., 2003).  
Furthermore, it has been well established that EGF 
signaling can be regulated via dynamic interactions 
between PLD2 (PA) and its binding partners (Lee et al., 
2009). In addition, EGF can induce dissociation 
between PLD2 and munc-18 to activate PLD2 (Lee et 
al., 2004). Activated EGFR can recruit PLCγ to EGFR 
complex, and PLD2 can activate PLCγ which can 
generate IP3and DAG for the activation of PKC (Jang 
et al., 2003). PLCγ can also serve as a GEF for 
dynamin (Choi et al., 2004). GTP-loaded dynamin and
PKC can activate PLD2, which can act as a GAP for 
dynamin to potentiate EGFR endocytosis (Park et al., 
2004; Lee et al., 2006). PA, generated by PLD 
activation, can recruit SOS to the plasma membrane.  
SOS acting as a GEF for Ras can activate the MAP 
kinase cascade (a key proliferative signaling pathwy) 
and eventually induce cell proliferation and 
transformation (Zhao et al., 2007). 
Cell growth signaling  
Cells regulate cellular homeostasis by using 
extracellular nutrients and growth signals, and 
malfunctions in this process cause severe diseases, such 
as, cancer and diabetes.  
PLD2 acts as a key regulator of growth signaling 
mainly via the control of the mammalian target of 
rapamycin (mTOR), which is a key target for cancer 
treatment (Ha et al., 2006). Both PLD2 and PA can 
affect mTor signaling. PA can directly interact with the 
FRB domain of mTOR and activate mTOR (Toschi et 
al., 2009). Rapamycin (an anti-cancer drug) can inhib t 
mTOR activation by competing with PA for mTOR 
(Fang et al., 2001).  
In addition, PLD can bind Raptor, which complex 
strongly with mTOR, and interact with Rheb (an 
upstream GTPase of mTOR) in a GTP-dependent 
manner (Sun et al., 2008).  
Furthermore, these interactions are required for the 
activation of mTOR complex and the mediation of 
growth signaling. 
Vesicle trafficking (endocytosis, and exocytosis)  
PLD is known to be implicated in vesicle trafficking, 
such as, in intracellular vesicle trafficking, endocytosis, 
and exocytosis (Jones et al., 1999). In addition, PA 
generation by PLD has been reported to be involved in 
vesicle fusion by mediating inner membrane curvature 
(Jenkins and Frohman, 2005). Many reports have 
suggested that PLD1 is essentially involved in secretion 
and exocytosis (Vitale et al., 2001; Vitale et al.,2002), 
but recently, PLD2 was also found to be required for 
exocytosis. For example, Lee et al. reported that PLD2 
is critically involved in insulin secretion by EGF in
primary pancreatic islets and in a pancreatic beta c ll 
line (Lee et al., 2008b). Also, PLD2 can induce 
angiotensin II-mediated aldosterone secretion from 
adrenal glomerulosa cells (Qin et al., 2010), and i 
addition to exocytosis, PLD2 is a well known essential 
mediator of receptor-mediated endocytosis and 
phagocytosis (Shen et al., 2001; Iyer et al., 2004). 
Furthermore, the overexpression of PLD2 wild-type 
can increase EGFR endocytosis, whereas the catalytic 
inactive PLD2 mutant does not (Shen et al., 2001). 
Moreover, mu-opioid receptor endocytosis and 
constitutive metabotropic glutamate receptor 
endocytosis can be affected by PLD2 activation (Koch 
et al., 2003; Bhattacharya et al., 2004). PLD2 activity 
can also regulate the phagocytosis of complement-
opsonized zymosan in macrophages (Iyer et al., 2004). 
Many authors have suggested that PA generation by 
PLD2 activation is critically implicated in endocytosis 
and exocytosis. However, recently, it was reported that
PLD2 itself, and not PLD2 activity, regulates 
endocytosis and phagocytosis (Lee et al., 2006; 
Mahankali et al., 2011). As we addressed above, PLD2 
has GAP and GEF functions (PLD2-PX domain, which 
acts as a GAP for dynamin, and a PLD2-PH domain, 
which acts as a GEF for Rac2). Furthermore, the 
PLD2-GAP function for dynamin can accelerate EGF-
mediated EGFR endocytosis and the PLD2-GEF 
function for Rac2 can increase phagocytosis in 
RAW264.7 macrophages. 
Cytoskeletal rearrangement 
Cells can undertake cytoskeletal changes by utilizing 
the dynamics of actin and tubulin (Berepiki et al.,2011; 
de Forges et al., 2012). These changes play a vital role 
in mediating a variety of cellular processes, such as, 
adhesion, spreading, migration, phagocytosis, and 
cytokinesis (Hynes, 2002). These processes are 
essential for pathophysiological functions, such as,
organ morphogenesis and metastasis (Fletcher and 
Mullins, 2010). Several authors have suggested that 
PLD2 has a close relationship with cytoskeletal 
dynamics. For example, PLD2 can directly interact 
with kinases (PKC and PtdIns(4)P 5-Kinase) and small 
G proteins (Ral, Arf1, Arf4, and Arf6) that modulate 
cytoskeletal dynamics (Jang et al., 2012). Furthermore, 
cytoskeletal proteins, such as, actin and tubulin, can
direct bind to PLD2 and inhibit its activity (Chae et al., 
2005). Also, PA generation by PLD2 activation can 
activate PtdIns(4)P 5-Kinase to generate PtdIns(4,5)P2, 
which is involved in actin polymerization (Moritz et al., 
1992).  
Also, integrin-mediated PA generation by PLD can 
recruit GTP-loaded Rac1 to the plasma membrane and 
be involved in activating Rac1 to mediate cell 
spreading and migration (Chae et al., 2008). Recently, 
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in addition to PA generation by PLD2 activation, PLD2 
(acting as a GEF) was found to be critically implicated 
in actin dynamics, for example, PLD2 can serve as a 
GEF for RhoA and Rac2 (Jeon et al., 2011; Mahankali 
et al., 2011).  
Furthermore, it has been reported that PLD2, acting as 
a GEF for RhoA, participates in LPA-mediated stress 
fiber formation and that PLD2, acting as a GEF for 
Rac2, is important for the mediations of migration and 
phagocytosis. 
Homology 
We used PLD2A protein sequences (protein ID : 
ENSP00000263088) and aligned sequences with 
Multiple Sequence Alignment program at the website 
of the European Bioinformatics Institute (EMBL-EBI), 
and found the following: 
- 55% sequence identity with PLD1a of Homo sapiens 
(protein ID: ENSP00000342793). 
- 89% sequence identity with PLD2 of Mouse (protein 
ID: ENSMUSP00000018429). 
- 85% sequence identity with PLD2 of Rat (protein ID:
ENSRNOP00000053831). 
- 57% sequence identity with PLD2 of Zebrafish 




Many reports have concluded that PLD2 is critically 
linked to the signals that mediate the processes 
involved tumorigenesis (transformation and tumor 
growth) and metastasis (Park et al., 2012). SOS, which 
activates the Ras-MAPK cascade, can be recruited to 
the plasma membrane by PLD2-derived PA generation, 
and eventually, MAPK signaling increases cell 
proliferation and transformation in NIH-3T3 cells 
(Zhao et al., 2007). As discussed above in cell growth 
signaling, PLD2 and PA can both directly affect mTor 
signaling, which is a main target of anti-cancer drugs, 
for example, rapamycin (a competitor of PA) is being 
used for tumor treatment.  
In addition, the expression level and activity of PLD2 
have been reported to be elevated in several cancers, 
including colorectal cancer and renal cancer (Zhao et 
al., 2000; Saito et al., 2007), and to be associated with 
tumor size and survival (Saito et al., 2007). 
Furthermore, a PLD2 polymorphism detected in 
colorectal cancer was found to be closely linked to the 
prevalence of the disease (Wood et al., 2007). In the 
terms of metastasis, PLD has been implicated in the 
secretions of matrix metalloproteinase (MMP)-2 and 
MMP-9 in glioma and colorectal cancers, respectively 
(Kang et al., 2008; Park et al., 2009).  
Also, the overexpression of active PLD2 has been 
reported to increase the serum-induced cell invasion of 
EL4 lymphoma cells and to promote the metastasis of 
EL4 lymphoma cells into liver in syngeneic mice 
(Knoepp et al., 2008).  
Recently, PLD2 inhibitor was found to block the 
invasion of breast cancer cell lines, such as, the MDA-
231, 4T1, and PMT cell lines (Scott et al., 2009). 
Therefore, the targeting of PLD2 and PA offers an 
important anti-tumor developmental strategy. 
Parkinson's disease 
Note 
Parkinson's disease is a representative 
neurodegenerative disorder. α-Synuclein is the main 
component of Lewy bodies, the hallmark of Parkinson'  
disease, and elevated wild-type α-synuclein levels and 
polymorphisms of the α-synuclein gene are known to 
be closely linked to the severity and risk of developing 
Parkinson's disease (Parnetti et al., 2013).  
Furthermore, a physical interaction between PLD2 and 
α-synuclein reported in vivo can inhibit PLD2 activity 
(Jenco et al., 1998). Furthermore, PLD2 silencing by 
siRNA and the overexpression of α-synuclein have 
been reported to be associated with unusual behavioral 
deficits (Gorbatyuk et al., 2010). Although the 
implications of PLD2 in Parkinson's disease are not 
clear, further studies on the relations between PLD2 
and α-Synuclein in Parkinson's disease are required. 
Alzheimer's disease 
Note 
PLD is also implicated in Alzheimer's disease, another 
neurodegenerative disorder, which is characterized by 
amyloid β accumulation in brain tissues.  
PLD1 is known to interact with β-amyloid precursor 
protein and presenilins (PS1/PS2), which can mediat 
the proteolysis of β-amyloid precursor protein (Cai et 
al., 2006; Jin et al., 2007). Recently, an in vivo PLD2 
KO mice study showed that PLD2 deficiency plays a 
role in protecting transgenic Alzheimer's disease mice 
from learning and memory deficits (Oliveira et al., 
2010). However, regardless of changes in amyloid β 
and β-amyloid precursor protein, loss of PLD2 has 
been reported to mediate these protective effects via the 
recovery of synaptic protein (PSD95 and 
synaptophysin) levels.  
These observations suggest that PLD2 could be a 
potential therapeutic target in Alzheimer's disease. 
Hypertension 
Note 
Hypertension is a major risk factor of cardiovascular 
diseases, such as, strokes and ischemic heart disease 
(Zhao et al., 2011). The etiology of hypertension is 
multi-factorial and includes genetic and environmental 
components. PLD elevation has been reported in 
vascular smooth muscle cells from spontaneously 
hypertensive rats (SHR; an animal model of 
hypertension) (Kondo et al., 1994; Freeman et al., 
1995), and recently, genome-wide association studies  
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(GWASs) showed that PLD2 is mutated (Arg172 to 
Cys) in patients with a hypertensive status (Hong et al., 
2010). Although further studies on the interrelationship 
between PLD2 and hypertension are required, these 
GWASs demonstrated the biological relevance of 
PLD2 in the pathophysiology of hypertension. 
To be noted 
Note 
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